title: Considerations for the design and conduct of a pharmacovigilance study involving mass drug administration in a resource-constrained setting.
authors.affiliation: Clinical Affairs, Pfizer, New York, New York, United States of America.
authors.forename: Demissie
authors.initials: D
authors.lastname: Alemayehu
authors.forename: Emma N
authors.initials: EN
authors.lastname: Andrews
authors.forename: Paul
authors.initials: P
authors.lastname: Glue
authors.forename: Charles A
authors.initials: CA
authors.lastname: Knirsch
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000871:Anthelmintics / Q000627:therapeutic use; D000977:Antiparasitic Agents / Q000627:therapeutic use; D003140:Communicable Disease Control / Q000379:methods; D004605:Elephantiasis, Filarial / Q000188:drug therapy; D006373:Helminthiasis / Q000188:drug therapy; D006801:Humans; D009855:Onchocerciasis / Q000188:drug therapy; D012552:Schistosomiasis / Q000188:drug therapy; D014141:Trachoma / Q000188:drug therapy; D014330:Tropical Medicine / Q000379:methods
chemical_list: D000871:Anthelmintics; D000977:Antiparasitic Agents